Establishment of papillary thyroid cancer organoid lines from clinical specimens

Front Endocrinol (Lausanne). 2023 Mar 13:14:1140888. doi: 10.3389/fendo.2023.1140888. eCollection 2023.

Abstract

Papillary thyroid cancer (PTC) is a common malignancy of the endocrine system, and its morbidity and mortality are increasing year by year. Traditional two-dimensional culture of cell lines lacks tissue structure and is difficult to reflect the heterogeneity of tumors. The construction of mouse models is inefficient and time-consuming, which is difficult to be applied to individualized treatment on a large scale. Clinically relevant models that recapitulate the biology of their corresponding parental tumors are urgently needed. Based on clinical specimens of PTC, we have successfully established patient-derived organoids by exploring and optimizing the organoid culture system. These organoids have been cultured stably for more than 5 passages and successfully cryopreserved and retried. Histopathological and genome analysis revealed a high consistency of the histological architectures as well as mutational landscapes between the matched tumors and organoids. Here, we present a fully detailed method to derive PTC organoids from clinical specimens. Using this approach, we have developed PTC organoid lines from thyroid cancer samples with a success rate of 77.6% (38/49) until now.

Keywords: 3D culture; clinical specimens; gene expression; histological characterization; organoid; papillary thyroid cancer; preclinical model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Mice
  • Organoids / metabolism
  • Thyroid Cancer, Papillary / pathology
  • Thyroid Neoplasms* / pathology

Grants and funding

This work was supported by the National Key R&D Program of China (2019YFA0906000), the Guangdong Basic and Applied Basic Research Foundation (2021A1515110618, 2022A1515011428), the Shenzhen Science and Technology Program (KCXFZ20211020163407011, JCYJ20210324105612034), the Shenzhen San-Ming Project (SZSM201612010), the Shenzhen Key Medical Discipline Construction Fund (No. SZXK017), and the Shenzhen High-level Hospital Construction Fund.